Safety, tolerability and preliminary efficacy results of ORB-CEL-M - a novel mesenchymal stromal cell therapy - in diabetic kidney disease: The multicenter, randomized, placebo-controlled, phase-1b/2a NEPHSTROM clinical trial

被引：0
|
作者：
Remuzzi, G.
Griffin, M.
Cockwell, P.
Maxwell, P.
Perico, N.
Ruggenenti, P.
Introna, M.
Finnerty, A.
Smythe, J.
Fibbe, W.
Elliman, S.
O'Brien, T.
机构：
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2024年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OC10
引用
收藏
页码：S172 / S172
页数：1
相关论文
共 43 条
  • [31] Safety and Efficacy of HL301 In Radiation Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer Receiving Curative Concurrent Chemoradiotherapy: A Multicenter, Randomized, Double-Blinded, Placebo- Controlled, Phase 2a Clinical Trial
    Kim, Kyung Hwan
    Kang, Nahyun
    Song, Si Yeol
    Kim, Hak Jae
    Kim, Yeon-Sil
    Oh, Mi Jin
    Cho, Jaeho
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : 432 - 438
  • [32] EFFICACY AND SAFETY OF LESINURAD (RDEA594), A NOVEL URAT1 INHIBITOR, IN COMBINATION WITH ALLOPURINOL IN ALLOPURINOL-REFRACTORY GOUT PATIENTS: RESULTS FROM A RANDOMIZED, BLINDED, PLACEBO-CONTROLLED, PHASE 2B EXTENSION STUDY
    Perez-Ruiz, F.
    Sundy, J.
    Krishnan, E.
    Hingorani, V.
    Welp, J.
    Rodgers, T.
    Manhard, K.
    Cravets, M.
    Hagerty, D.
    Quart, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 439 - 439
  • [33] Efficacy and Safety of Lesinurad (RDEA594), A Novel Uricosuric Agent, Given In Combination with Allopurinol in Allopurinol-Refractory Gout Patients: Preliminary Results from the Randomized, Double-Blind, Placebo-Controlled, Phase 2B Extension Study.
    Sundy, John
    Perez-Ruiz, Fernando
    Krishnan, Eswar
    Hingorani, Vijay
    Welp, Jody
    Suster, Matt
    Manhard, Kimberly
    Cravets, Matt
    Hagerty, David
    Quart, Barry
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S398 - S399
  • [34] NOVEL, FIRST-IN-CLASS, FATTY ACID SYNTHASE (FASN) INHIBITOR TVB-2640 DEMONSTRATES ROBUST CLINICAL EFFICACY AND SAFETY IN A GLOBAL PHASE 2 RANDOMIZED PLACEBO-CONTROLLED NASH TRIAL (FASCINATE-1) CONDUCTED IN THE US AND CHINA
    Loomba, Rohit
    Rinella, Mary E.
    Harrison, Stephen A.
    Wong, Vincent
    Ratziu, Vlad
    Gores, Gregory J.
    Neuschwander-Tetri, Brent A.
    Mohseni, Rizwana
    Lucas, Kathryn Jean
    Gutierrez, Julio A.
    Perry, Robert
    Rahimi, Robert S.
    Trotter, James F.
    Deng, Hong
    Xie, Qing
    Zhang, Jing
    Wu, Lixian
    You, Hong
    Zhong, Bihui
    Hou, JinLin
    Yang, Yongfeng
    Lu, Yan
    He, Handan
    Palmer, Melissa
    Wu, Jinzi
    Grimmer, Katharine
    McCulloch, William
    O'Farrell, Marie
    Martins, Eduardo B.
    Kemble, George
    Shi, Junping
    HEPATOLOGY, 2021, 74 : 95A - 96A
  • [35] Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction
    Chakrabarti, Anjan K.
    Feeney, Kristin
    Abueg, Cassandra
    Brown, David A.
    Czyz, Ewa
    Tendera, Michal
    Andras Janosi
    Giugliano, Robert P.
    Kloner, Robert A.
    Weaver, W. Douglas
    Bode, Christoph
    Godlewski, Jacek
    Bela Merkely
    Gibson, C. Michael
    AMERICAN HEART JOURNAL, 2013, 165 (04) : 509 - +
  • [36] EFFICACY AND SAFETY OF BMS-986263, A NOVEL TARGETED LIPID NANOPARTICLE DELIVERING HSP47 siRNA, IN PATIENTS WITH ADVANCED HEPATIC FIBROSIS: PART 1 WEEK 12 RESULTS FROM A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Lawitz, Eric J.
    Revankar, Ratna
    Shevell, Diane
    Tirucherai, Giridhar
    Soule, Benjamin
    Duchesne, Dominique
    Du, Shuyan
    Alkhouri, Naim
    Coste, Angie
    Poordad, Fred
    Charles, Edgar D.
    HEPATOLOGY, 2019, 70 : 87A - 88A
  • [37] RESULTS FROM A PHASE 2A, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF JNJ-40346527, AN ORAL CSF-1R INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE DISEASE-MODIFYING ANTIRHEUMATIC DRUG THERAPY
    Genovese, M. C.
    Hsia, E.
    Belkowski, S.
    Chien, C.
    Masterson, T.
    Thurmond, R.
    Manthey, C.
    Yan, D.
    Ge, T.
    Greenspan, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 224 - 225
  • [38] Efficacy and Safety of a Single Intra-Articular Injection of MM-II, a Novel Suspension of Large, Empty, Multilamellar Liposomes, in People with Painful Knee OA: Results of a 26-Week, Phase 2b, Placebo-Controlled, Double-Blind, Randomized Trial
    Thomas, Schnitzer
    Rovsing, Helene
    Lau, Edith
    Boll, Sidsel
    Brahmachari, Ballari
    Chou, Richard
    Joshi, Tarini
    Wechsler, Roni
    Yao, Siu-Long
    Weiner, Sveta
    Bihlet, Asger
    Conaghan, Philip
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2342 - 2344
  • [39] PRELIMINARY RESULTS OF A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, SINGLE-CENTER PHASE 1 CLINICAL TRIAL TO EVALUATE SAFETY, TOLERABILITY, IMMUNOGENICITY AND EFFICACY OF CAF01 AND ALUMINUM HYDROXIDE AS ADJUVANTS FOR THE MALARIA VACCINE CANDIDATE GMZ2 IN HEALTHY ADULT AFRICAN VOLUNTEERS
    Ngoa, Ulysse Ateba
    Adegnika, Ayola Akim
    Agobe, Jean Claude Dejon
    Massinga-Loembe, Marguerite
    Theisen, Michael
    Kremsner, Peter G.
    Mordmueller, Benjamin
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2015, 93 (04): : 505 - 506
  • [40] SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF A NOVEL GLP-1/FGF21 DUAL AGONIST HEC88473 IN TYPE 2 DIABETES PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 1b/2a MULTIPLE-ASCENDING-DOSE STUDY
    Xiang, Lin
    Ding, Hua Yan
    Yan, Jiangyu
    Luo, Lin
    Zhang, Hong
    Xie, Can
    Peng, Yu Yu
    Chen, Hong
    Li, Qian Qian
    Li, Xiao Ping
    Zhuang, Yu Lei
    Guo, Linfeng
    HEPATOLOGY, 2024, 79 (02) : E67 - E68
12345